Concepts (218)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 21 | 2025 | 632 | 5.380 |
Why?
|
| Early Detection of Cancer | 10 | 2022 | 414 | 2.070 |
Why?
|
| Occult Blood | 8 | 2022 | 32 | 1.920 |
Why?
|
| Colonoscopy | 9 | 2022 | 252 | 1.770 |
Why?
|
| Colonic Neoplasms | 6 | 2024 | 262 | 1.300 |
Why?
|
| Adenoma | 3 | 2022 | 146 | 1.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 4 | 2025 | 199 | 0.990 |
Why?
|
| Lymphocytes | 3 | 2023 | 363 | 0.930 |
Why?
|
| Mass Screening | 7 | 2022 | 828 | 0.830 |
Why?
|
| Colonic Polyps | 2 | 2021 | 85 | 0.760 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 13 | 0.710 |
Why?
|
| Polyps | 1 | 2021 | 43 | 0.680 |
Why?
|
| Neoplasm Staging | 8 | 2024 | 1360 | 0.640 |
Why?
|
| Anemia | 2 | 2023 | 350 | 0.600 |
Why?
|
| Guaiac | 1 | 2017 | 1 | 0.550 |
Why?
|
| Xylenes | 4 | 2007 | 13 | 0.520 |
Why?
|
| Prognosis | 9 | 2023 | 5008 | 0.510 |
Why?
|
| Inflammation | 3 | 2024 | 1519 | 0.500 |
Why?
|
| Body Composition | 3 | 2024 | 550 | 0.490 |
Why?
|
| Anti-Infective Agents, Local | 5 | 2007 | 67 | 0.480 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 10 | 0.420 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2022 | 18 | 0.370 |
Why?
|
| Diabetes Complications | 1 | 2013 | 207 | 0.360 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 222 | 0.360 |
Why?
|
| Neutrophils | 3 | 2023 | 360 | 0.360 |
Why?
|
| Aspirin | 1 | 2013 | 220 | 0.360 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 305 | 0.350 |
Why?
|
| Trypsin | 1 | 2010 | 88 | 0.340 |
Why?
|
| Aged | 14 | 2025 | 21406 | 0.340 |
Why?
|
| Microbiological Techniques | 1 | 2010 | 34 | 0.330 |
Why?
|
| Robotic Surgical Procedures | 2 | 2025 | 222 | 0.330 |
Why?
|
| Humans | 38 | 2025 | 132013 | 0.330 |
Why?
|
| Catheters | 1 | 2010 | 87 | 0.320 |
Why?
|
| C-Reactive Protein | 3 | 2025 | 464 | 0.320 |
Why?
|
| Drug Utilization | 1 | 2011 | 166 | 0.320 |
Why?
|
| Anti-Bacterial Agents | 6 | 2011 | 2554 | 0.320 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 246 | 0.300 |
Why?
|
| Staphylococcus aureus | 2 | 2010 | 479 | 0.290 |
Why?
|
| Thymol | 1 | 2007 | 2 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2024 | 2164 | 0.270 |
Why?
|
| Retrospective Studies | 9 | 2024 | 17374 | 0.270 |
Why?
|
| Pneumonia | 1 | 2011 | 334 | 0.270 |
Why?
|
| Urinary Catheterization | 1 | 2007 | 86 | 0.260 |
Why?
|
| Middle Aged | 12 | 2025 | 28968 | 0.260 |
Why?
|
| Equipment Contamination | 2 | 2005 | 41 | 0.260 |
Why?
|
| Chlorhexidine | 5 | 2006 | 47 | 0.250 |
Why?
|
| Escherichia coli | 2 | 2010 | 995 | 0.250 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 1017 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 742 | 0.250 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 223 | 0.250 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3137 | 0.250 |
Why?
|
| Male | 19 | 2025 | 64914 | 0.240 |
Why?
|
| Prosthesis-Related Infections | 3 | 2005 | 187 | 0.230 |
Why?
|
| Female | 22 | 2025 | 70643 | 0.230 |
Why?
|
| Glycopeptides | 1 | 2005 | 27 | 0.230 |
Why?
|
| Urinary Tract Infections | 2 | 2007 | 317 | 0.230 |
Why?
|
| Socioeconomic Factors | 4 | 2021 | 902 | 0.230 |
Why?
|
| Predictive Value of Tests | 3 | 2022 | 2311 | 0.220 |
Why?
|
| Vancomycin | 1 | 2005 | 222 | 0.200 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1411 | 0.200 |
Why?
|
| Scotland | 3 | 2021 | 23 | 0.200 |
Why?
|
| Staphylococcal Infections | 3 | 2005 | 569 | 0.190 |
Why?
|
| United Kingdom | 2 | 2013 | 235 | 0.190 |
Why?
|
| Prospective Studies | 5 | 2021 | 6568 | 0.180 |
Why?
|
| Logistic Models | 2 | 2018 | 1839 | 0.180 |
Why?
|
| Age Factors | 3 | 2024 | 2911 | 0.170 |
Why?
|
| Sex Factors | 2 | 2016 | 1351 | 0.170 |
Why?
|
| Candida albicans | 4 | 2007 | 90 | 0.170 |
Why?
|
| Survival Analysis | 3 | 2021 | 1572 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 256 | 0.160 |
Why?
|
| Time Factors | 4 | 2016 | 6441 | 0.160 |
Why?
|
| Rabbits | 6 | 2007 | 673 | 0.160 |
Why?
|
| Sensitivity and Specificity | 4 | 2022 | 2139 | 0.150 |
Why?
|
| Rectal Neoplasms | 2 | 2024 | 81 | 0.150 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1998 | 4 | 0.140 |
Why?
|
| Emergencies | 2 | 2016 | 186 | 0.140 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 326 | 0.140 |
Why?
|
| Spain | 1 | 2017 | 65 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.130 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 686 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2016 | 77 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2022 | 1697 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 96 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1127 | 0.120 |
Why?
|
| Minocycline | 4 | 2002 | 42 | 0.120 |
Why?
|
| Pregnancy, Twin | 1 | 2017 | 190 | 0.120 |
Why?
|
| Psychosocial Deprivation | 1 | 2015 | 5 | 0.120 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12987 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1439 | 0.110 |
Why?
|
| Iron | 1 | 2018 | 302 | 0.110 |
Why?
|
| Rifampin | 4 | 2002 | 120 | 0.110 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 150 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1457 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 184 | 0.110 |
Why?
|
| Colon | 1 | 2017 | 370 | 0.110 |
Why?
|
| Survival Rate | 2 | 2016 | 2188 | 0.110 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2007 | 827 | 0.110 |
Why?
|
| Feces | 3 | 2022 | 753 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 216 | 0.100 |
Why?
|
| Obesity | 1 | 2025 | 2397 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2013 | 53 | 0.100 |
Why?
|
| Catheters, Indwelling | 3 | 2007 | 157 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 291 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 550 | 0.090 |
Why?
|
| Length of Stay | 2 | 2024 | 1380 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1230 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 761 | 0.090 |
Why?
|
| Sonication | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2022 | 322 | 0.080 |
Why?
|
| Colectomy | 2 | 2024 | 84 | 0.080 |
Why?
|
| Hospitals, Veterans | 2 | 2011 | 346 | 0.080 |
Why?
|
| Staphylococcus epidermidis | 2 | 2002 | 40 | 0.080 |
Why?
|
| Antibiotics, Antitubercular | 2 | 2002 | 34 | 0.080 |
Why?
|
| Adult | 6 | 2024 | 31563 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1305 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 5409 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 7105 | 0.080 |
Why?
|
| Algorithms | 1 | 2016 | 1718 | 0.080 |
Why?
|
| Candidiasis | 2 | 2007 | 137 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 60 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2017 | 3731 | 0.070 |
Why?
|
| Health Care Costs | 1 | 2011 | 415 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2021 | 5166 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 2005 | 258 | 0.070 |
Why?
|
| Heart Valve Prosthesis | 2 | 2002 | 328 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2024 | 1036 | 0.060 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2007 | 76 | 0.060 |
Why?
|
| Antisepsis | 1 | 2006 | 8 | 0.060 |
Why?
|
| Bacterial Infections | 2 | 2007 | 323 | 0.060 |
Why?
|
| Disinfectants | 1 | 2006 | 29 | 0.060 |
Why?
|
| Candida | 1 | 2006 | 84 | 0.060 |
Why?
|
| Teicoplanin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 264 | 0.060 |
Why?
|
| Bacteria | 1 | 2007 | 522 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 664 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 26 | 0.050 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2007 | 496 | 0.050 |
Why?
|
| Intra-Abdominal Fat | 1 | 2022 | 61 | 0.050 |
Why?
|
| Bacterial Adhesion | 3 | 1998 | 106 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2024 | 260 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 241 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 120 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2021 | 249 | 0.040 |
Why?
|
| Animals | 7 | 2007 | 34804 | 0.040 |
Why?
|
| Catheterization, Central Venous | 2 | 1998 | 139 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 1998 | 36 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 42 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 24 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 20 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2024 | 523 | 0.040 |
Why?
|
| Blood | 1 | 1998 | 103 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 569 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1998 | 63 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 135 | 0.030 |
Why?
|
| Klebsiella Infections | 1 | 1997 | 60 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 606 | 0.030 |
Why?
|
| Conservative Treatment | 1 | 2017 | 41 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 1997 | 85 | 0.030 |
Why?
|
| Lymphatic Vessels | 1 | 2016 | 36 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1998 | 175 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2016 | 103 | 0.030 |
Why?
|
| Equipment Design | 1 | 1998 | 599 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 136 | 0.030 |
Why?
|
| Iran | 1 | 2016 | 94 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 494 | 0.030 |
Why?
|
| Consanguinity | 1 | 2016 | 121 | 0.030 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 141 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 442 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 256 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10931 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 133 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 956 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 622 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2017 | 418 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1993 | 58 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 662 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2014 | 389 | 0.020 |
Why?
|
| Monocytes | 1 | 1993 | 342 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 1993 | 278 | 0.020 |
Why?
|
| Young Adult | 2 | 2016 | 9952 | 0.020 |
Why?
|
| Pregnancy | 2 | 2017 | 7554 | 0.020 |
Why?
|
| Brain Injuries | 1 | 1993 | 716 | 0.020 |
Why?
|
| Silver Sulfadiazine | 2 | 1998 | 9 | 0.020 |
Why?
|
| Colony Count, Microbial | 2 | 1998 | 87 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1177 | 0.020 |
Why?
|
| Drug Combinations | 2 | 1998 | 280 | 0.020 |
Why?
|
| Catheterization | 1 | 2006 | 241 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 20544 | 0.010 |
Why?
|
| Bacillus | 1 | 2002 | 37 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 14736 | 0.010 |
Why?
|
| Drug Stability | 1 | 1998 | 59 | 0.010 |
Why?
|
| Mannose | 1 | 1997 | 23 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1998 | 4684 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 136 | 0.010 |
Why?
|
| Fimbriae, Bacterial | 1 | 1997 | 44 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 431 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 128 | 0.010 |
Why?
|
| DNA Fingerprinting | 1 | 1997 | 109 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1997 | 62 | 0.010 |
Why?
|
| Half-Life | 1 | 1996 | 160 | 0.010 |
Why?
|
| Gram-Positive Bacteria | 1 | 1996 | 48 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1998 | 665 | 0.010 |
Why?
|
| Gram-Negative Bacteria | 1 | 1996 | 73 | 0.010 |
Why?
|
| Child | 1 | 2016 | 25765 | 0.010 |
Why?
|
| Ganglia, Parasympathetic | 1 | 1993 | 1 | 0.010 |
Why?
|
| Spinal Cord Injuries | 1 | 1997 | 287 | 0.010 |
Why?
|
| Cross Infection | 1 | 1997 | 342 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1993 | 56 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 1554 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1993 | 83 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1993 | 120 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 1453 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1993 | 149 | 0.010 |
Why?
|
| Microglia | 1 | 1993 | 138 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 13050 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 3043 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1993 | 673 | 0.000 |
Why?
|
| Texas | 1 | 1998 | 3627 | 0.000 |
Why?
|